Biocon Q2 Revenue Growth Muted At 2%: Shipping Disruptions Delay 5% Of Biopharma Sales | ET Now
ET Now · 07 Nov 2026 · 1 min
Management interview of Biocon Ltd (BIOCON), with 1 key numbers discussed.
- Shreehas Tambe, MD & CEO, Biocon
Biocon's Q2 performance remained on track with strategic plans despite shipping disruptions deferring about 5% of biopharma sales. MD & CEO Shreehas Tambe clarified that these delays were timing-related and recognised in October, spilling into Q3. The company does not anticipate further shipping deferral impacts in Q3. Management reiterated that the second half of the fiscal year is expected to be stronger than the first half.